These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11340533)

  • 1. Resistance to trimethoprim-sulfamethoxazole.
    Huovinen P
    Clin Infect Dis; 2001 Jun; 32(11):1608-14. PubMed ID: 11340533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
    Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
    Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ.
    Leoung GS; Stanford JF; Giordano MF; Stein A; Torres RA; Giffen CA; Wesley M; Sarracco T; Cooper EC; Dratter V; Smith JJ; Frost KR;
    J Infect Dis; 2001 Oct; 184(8):992-7. PubMed ID: 11574913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases.
    Dworkin MS; Williamson J; Jones JL; Kaplan JE;
    Clin Infect Dis; 2001 Aug; 33(3):393-8. PubMed ID: 11438910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
    Grim SA; Rapp RP; Martin CA; Evans ME
    Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis.
    Le TP; Miller LG
    Clin Infect Dis; 2001 Sep; 33(5):615-21. PubMed ID: 11486284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.
    Martin JN; Rose DA; Hadley WK; Perdreau-Remington F; Lam PK; Gerberding JL
    J Infect Dis; 1999 Dec; 180(6):1809-18. PubMed ID: 10558935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimethoprim-sulfamethoxazole.
    Smilack JD
    Mayo Clin Proc; 1999 Jul; 74(7):730-4. PubMed ID: 10405706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Choice of treatment in recurrent urinary infections in childhood].
    Sánchez Bayle M; Barrio Pérez ML; Estepa Soto MR; López Verde L
    An Esp Pediatr; 1984 Jan; 20(1):28-32. PubMed ID: 6608301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thiamphenicol versus trimethoprim-sulfamethoxazole in bacterial exacerbations of chronic unspecific respiratory tract diseases. A controlled study].
    Medici TC; Hermann R; Lualdi P; Frigerio G
    Schweiz Med Wochenschr; 1980 Jul; 110(30):1128-37. PubMed ID: 6999618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment.
    Green SL; Mayhew IG; Brown MP; Gronwall RR; Montieth G
    Can J Vet Res; 1990 Apr; 54(2):215-22. PubMed ID: 2357657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.
    Raz R; Chazan B; Kennes Y; Colodner R; Rottensterich E; Dan M; Lavi I; Stamm W;
    Clin Infect Dis; 2002 May; 34(9):1165-9. PubMed ID: 11941541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia.
    Madhi SA; Cutland C; Ismail K; O'Reilly C; Mancha A; Klugman KP
    Clin Infect Dis; 2002 Nov; 35(9):1120-6. PubMed ID: 12384847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing antibiotic resistance.
    Gupta K
    Dis Mon; 2003 Feb; 49(2):99-110. PubMed ID: 12601340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya.
    Chiller TM; Polyak CS; Brooks JT; Williamson J; Ochieng B; Shi YP; Ouma P; Greene C; Hamel M; Vulule J; Bopp C; Slutsker L; Mintz E
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):165-9. PubMed ID: 19357424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
    Jordano Q; Falcó V; Almirante B; Planes AM; del Valle O; Ribera E; Len O; Pigrau C; Pahissa A
    Clin Infect Dis; 2004 Jun; 38(11):1623-8. PubMed ID: 15156452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Dis Mon; 2003 Feb; 49(2):129-47. PubMed ID: 12601342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
    Talan DA; Naber KG; Palou J; Elkharrat D
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S54-66. PubMed ID: 15037329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections.
    Metlay JP; Strom BL; Asch DA
    J Antimicrob Chemother; 2003 Apr; 51(4):963-70. PubMed ID: 12654756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate.
    Wagenlehner FM; Wagenlehner C; Schinzel S; Naber KG;
    Eur Urol; 2005 Apr; 47(4):549-56. PubMed ID: 15774257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.